13th Annual Meeting of The Japanese Association of Antiviral Chemotherapy



Download 81 Kb.
Date18.05.2018
Size81 Kb.
13th Annual Meeting of The Japanese Association of Antiviral Chemotherapy

(Program)
January 27 (Mon)
9:15 Welcome
1. Chemistry and Pre-clinical Development (1) Chair: Tokumi Maruyama
9:30 A1-1

Design, synthesis and analysis of antiviral nucleosides bearing pryrrolepolyamides binding to DNA

Etsuko Kawashima1, Daisuke Ito1, 〇Yuhsuke Ohba1, Tokumi Maruyama2, Kazuo Kamaike1, Yuhsuke Terui1, Tairo Ohshima1

(1Tokyo University of Pharmacy and Life Science, 2Tokushima Bunri University)


9:43 A1-2

Synthesis and Antiviral Activity of 1’-C-Carbon-substituted 2’-deoxy-4’-thiopyrimidine Nucleoside



    • Kazuhiro Haraguchi, Haruhiko Takahashi, Hiromichi Tanaka

(School of Pharmaceutical Sciences, Showa University)
9:56 A1-3

Synthesis of 2’-carbon-substituted d4T analogues



    • Hiroki Kumamoto, Sayoko Onuma, Kazuki Deguchi, Yuich Yoshimura, Hiromichi Tanaka

(School of Pharmaceutical Sciences, Showa University)
10:09 A1-4

Synthesis and antiviral activity of 3’-fluorocarbocyclic oxetanocin A



    • Tokumi Maruyama1, Yoshiko Sato1, Kenji Abe2, Kohtaro Yamamoto2

(1Fac. of Pharm. Sci. Tokushima Bunri Univ., 2Dept. Viol., Med. Res. Inst., Tokyo Medical and Dental Univ.)
10:2210:45 Break

2. Chemistry and Pre-clinical Development (2) Chair: Hiromichi Tanaka
10:45 A1-5

Discovery of 4’-C-substituted purine 2’-deoxynucleosides havng anti-HIV activity



    • Satoru Kohgo1, Kohei Yamada1, Kenji Kitano1, Noriyuki Ashida1, Shinji Sakata1, Hiroyuki Hayakawa1, Daisuke Nameki2, Eiichi Kodama2, Masao Matsuoka2, Hiroaki Mitsuya3, Hiroshi Ohrui4

(1Biochemicals Division, Yamasa Coroporation,2Institute for Virus Research, Kyoto University, 3School of Medicine, Kumamoto University, 4Graduate School of Life Science, Tohoku University4)
10:58 A1-6

Biological Activities of 4’-Modified Nucleosides against HIV and HBV



    • Kenji Kitano1, Kohei Yamada1, Satoru Kohgo1, Noriyuki Ashida1, Shinji Sakata1, Hiroyuki Hayakawa1, Eiichi Kodama2, Hiroaki Mitsuya3, Hiroshi Ohrui4

(1Biochemical Division, Yamasa Corporation, 2Institute for Virus Research, Kyoto University, 3School of Medicine, Kumamoto University, 4Graduate School of Life Science, Tohoku University)
11:11 A1-7

Synthesis and evaluation of AZT 5’-terpenylphoshates for skin penetraion enhancement



    • Chieko Koshiba1, Mineo Saneyoshi1,2, Hisashi Nishimura3, Akinobu Hamada3, Takeo Kawaguchi4,

(1Dep. Biol. 2Biotech,, Center, Teikyou Univ. Sci. & Technol. 3Kumamoto Univ., Hospital, 4Josai Univ.)
11:24 A1-8

Synthesis of enantiomer of Zintevir and its anti-HIV-1 activity

○Hidehito Urata1, Tetsuya Kumashiro1, Toru Otake2, Takuya Kawahata2, Masao Akagi1

(1Osaka Univ. of Pharm. Sci. and 2Osaka Pref. Inst. of Public Health)



3. Hepatitis C VirusCancer Chair:Michinori Kohara
11:37 A1-9

An anti-BVDV assay by a modified plaque reduction method.



    • Koichiro Yanagida1,2, Masanori Baba1

(1Center for Chr. Viral Dis., Faculty of Med., Kagoshima, Univ., 2PLANOVA division, Asahi Kasei Corp.)

11:50 A1-10

Design of alkylating pryrroe-imidazole polyamides: Relationship between sequence-specificity and antitumor activity

○Toshikazu Bando1, Akihiko Narita1, Noboru Fukuda2, Hiroshi Sugiyama1

(1Institute Biomaterials and Bioengineering, Tokyo Medical and Dental Univ., 2Second Department of Internal Medicine, Nihon Univ. School of Medicine)
12:03 A1-11

Inhibition of Hepatitis C Virus Replication by RNA Interference

○Naoya Sakamoto1, Yoko Tanabe1, Nobuyuki Enomoto1, Takanori Yokota2, Shinya Maekawa1, Cheng-Hsin Chen1, Li Ye2, Hedehiro Mizusawa2, and Mamoru Watanabe1

(1Dept. Gastroenterology-Hepatology and 2Dept. Neurology, Tokyo Med. and Dent. Univ.)


12:16 A1-12

Evolution of hepatitis C virtus after mother to child transmission-role of humoral and cellular responses



    • Haruki Komatsu, Ayano Inui, Tomoo Fujisawa

(Department of Pediatrics, National Defense Medical College)
12:2913:35 Lunch
4. Retrovirus Infections (1) Chair: Toru Ohtake
13:35 P1-13

Breast cancer resistance proteinx (BCRP) induces cellular resistance to HIV-1 nucleoside reverse transctriptase inhibitors

○Xin Wang, Takao Nitanda, Mika Okamoto, Masanori Baba

(Hum. Retrovir., CCVD, Kagoshima University)


13:48 P1-14

Novel nevirapine-resistant human immunodeficiency virus type 1 variants isolated from antiretroviral-naïve patients.

○Atsuko Hachiya1, Eiichi Kodama2, Mieko Ikeuchi2, Shigeyoshi Harada3, Hiroyuki Gatanaga1, Saori Matsuoka1, Kiyoto Tsuchiya1, Satoshi Kimura1, Masao Matsuoka2, Hiroaki Mitsuya3, Shinichi Oka1

(1AIDS Clinical Center, International Medical Center of Japan, Tokyo, 2Laboratory of Virus Immunology, Institute of Virus Research, Kyoto University, Kyoto, and 3the Second Department of Internal Medicine, Kumamoto University School of Medicine, Kumamoto, Japan)


14:01 P1-15

Pathways for the Emergence of Multi-Dideoxynucleoside- Resistant Human Immunodeficiency Virus Type 1 Variants (HIV-1MDR): Virological and Enzymological Analyses

○Shigeyoshi Harada, Shintaro Matsumi, Maki Ichinomiya Hiroaki Mitsuya

(Department of Internal Medicine II, Kumamoto University School of Medicine)


14:14 P1-16

Characterization of fusion inhibitor resistant HIV variants in vitro.

○Eiichi Kodama, Daisuke Nameki, Mieko Ikeuchi, Masao Matsuoka

(Lab. Virus Immunol., Inst. Virus Res., Kyoto Univesity)


5. Retrovirus Infections (2) Chair: Eiich Kodama
14:27 P1-17

Evaluation of HIV-1 phenotype using co-receptor inhibitors

○Haruyo Mori1, Yoko Kojima1, Takuya Kawahata1, Toru Otake1, Masashi Tatsumi2

(1Lab. Pathol., Osaka Pref. Inst. Public Health, 2Dept. Vet. Science, Natl. Inst. Infect. Des.)


14:40 P1-18

Evaluation of candidate compounds for inhibitory effect of HIV-1 with a model of cell fusion.

○Eiko Suzuki1, Kyoko Hayashi2, Sachiko Okitsu1, Shigeru Morikawa3, and Hiroshi Ushijima1

(1Dept. of Developmental Medicine, Graduate School of Medicine, University of Tokyo, 2Toyama Medical and Pharmaceutical University and 3National Institute of Infectious Disease)


14:53 P1-19

TYA5/TYB5: Novel Nonpeptidic Protease Inhibitors (PIs) Containing a Hydroxyethylamine Dipeptide Isostere Potent against Multi-PI-resistant HIV In Vitro.

○Yasuhiro Koh1, Hirokazu Tamamura2, Tomonori Yamasaki2, Manabu Aoki1, Kenji Maeda1, Nobutaka Fujii2, Hiroaki Mitsuya1

(1Department of Internal Medicine II, Kumamoto University School of Medicine, 2Graduate School of Pharmaceutical Sciences, Kyoto University)


15:06 P1-20

Suppression of HIV-1 gene expression by siRNA

○Masaaki Hayafune1, Wee-Sung Park1, Naoko Miyano-Kurosaki1,2, Hiroshi Takaku1,2

(1Dept. Ind. Chem. & 2High Tech. Res. Center, Chiba Inst. Tech.)


15:1915:45 Break
6. Other Viral Infections (1) Chair: Masayuki Saijo
15:45 P1-21

Inhibitory Effect of West Nile Virus Infection by JNK Inhibitor

○Tetsuya Mizutani1), Masayuki Kobayashi1), Yuki Eshita3), Takashi Kimura2), Kazuya Shirato1, Yoshihiko Ako1, Hirotsugu Miyoshi1, Takashi Umemura1, Hiroaki Kariwa1, Ikuo Takashima1

(1Public Health, 2Comp. Pathol., Hokkaido Univ., 3Dept. Infectious Disease, Oita Med. Univ.)


15:58 P1-22

Ribivirin therapy for subacute sclerosing panencephalitis (SSPE)

○Mitsuaki Hosoya1, Akemi Tomoda2, Shuichi Mori3, Tatsuo Suzutani3, Shiro Shigeta3, Hitoshi Suzuki1

(1Department of Pediatrics and 3Microbiology, Fukushima Medical University School of Medicine and 2Department of Child Development, Kumamoto University School of Medicine)


16:11 P1-23

Establishment of testing model for anti-adenovirus effect using cotton rat eye

○Hisatoshi Kaneko1, Shuichi Mori1, Shiro Shigeta1, Tatsuo Suzutani1, Kazuhiro Ohgami3, Shigeaki Ohno3, Koki Aoki4

(1Department of Microbiology, 2Department of Ophtalmology, Fukushima Medical University, 3Department of Ophtalmology and Visual Sciences, Hokkaido University Graduate School of Medicine, 4Aoki Eye Clinic)


7. Other Viral Infections (2) Chair: Mineo Saneyoshi
16:24 P1-24

Treatment of Crimean-Congo hemorrhagic fever with rebavirin,

○Masayuki Saijo1, Tang Qing2, Shigeru Morikawa1, Akihiko Maeda1, Ichiro Kurane1

(1Dept Virol 1, National Institute of Infectious Disease, Tokyo, Japan, 2Dept 2nd Viral Hemorrhagic Fever, Chinese CDC, Beijing, China)


16:37 P1-25

A treatment for smallpox infection due to bioterrorism



(Dept. Ophthalmol. & Visual Neuroscience, Univ. Tokushima)
16:50 P1-26

Inactivation and Antiviral Effects of Guaba Tea Extract against Several Enveloped Viruses

○Shiro Shigeta, Kennji Konno, Shuichi Mori

(Department of Microbiology, Fukushima Medical University)


17:03 P1-27

Mechanisms of virus neutralization by antiviral monoclonal antibodies.

○Takashi Irie, Akihiko Kawai

(Dept. Molec. Microbiol. Grad. School Pharmaceut. Sci. Kyoto Univ.)


8. Orthomyxovirus and Paramyxovirus Infections Chair: Masanobu Ohuchi
17:16 P1-28

Therapeuteic effect of NA inhibitor, protease inhibitor and antiserum on neurovirulent influenza virus-infected mice

○Masanobu Ohuchi, Yasuko Tanaka, Sachiyo Omori, Reiko Ohuchi

(Dept. Microbiol., Kawasaki Medical School)


17:29 P1-29

Evaluating the immune responses stimulated by CpG oligodeoxynucleotides

○Mieko Hayashi1, Naoko Miyao-Kurosaki1,2, Takayuhi Abe1, Ryouji Ueki3, Mayuka Yano3, Masayuki Fujii3, G. Hartmann4, Hiroshi Takaku1,2

(1Dept. Ind. Chem. & 2High Tech. Res. Center, Chiba Inst. Tech., 3Dept. Bio & Enviro. Chem. Kinki Univ., 4Dept. Internal and Div. Clinical Pharmacology, Univ. Munich, Germany.)


17:42 P1-30

Antiviral Activity of PEG-Interferon Against Several RNA and DNA Viruses

○Shuichi Mori, Shiro Shigeta, Emiko Endo, Tatsuo Suzutani

(Department of Microbiology, Fukushima Medical University)


17:55 P1-3

Novel Anti-rhinovirus Compound MRL-2471 Targets the Non-structural Proteins 2B and 3A of Rhinovirus

〇Masanobu Agoh1, Yumi Agoh1,3, YoshiroYamamura1, Masaki Tsutsui1, Takashi Okamoto1, Reeko Iwata1, Yoshiharu Matsuura2, Takashi Kurimura2, and Hiroshi Ichimura3

(1Cent. Res. Labs., Maruishi Pharm. Co., Ltd., 2Inst. Microb. Dis., Osaka Univ. 3Dept. Viral Infect. Ctrl., Grad. Sch. Med. Sci., Kanazawa Univ.)



128日(火)January 28 (Tue)
9. Herpesvirus Infections Chair: Tatsuo Suzutani
9:00 A2-32

Susceptibility of herpes simplex virus type 1 (HSV-1), which expresses viral thymidine kinase translated from the second methionine, to antiviral agents

○Masayuki Saijo, Tatsuo Suzutani, Shigeru Morikawa, Akihiko Maeda, Ichiro Kurane

(1Dept Virol 1, National Institute Infectious Disease, Tokyo 208-0011, Japan, 2Dept Microbiol, Fukushima Medical University, Fukushima, Japan)


9:13 A2-33

Preventive effect of lesion formation of aciclovir eyedrop against herpes simplex keratitis in rabbits

○Makoto Kajima1, So Hata1, Takeshi Naito1, Hiroshi Shiota1, Tomohiro Okamoto2, Tooru Oguro2, & Toshio Kasama2

(1Dept. Ophthalmol. & Visual Neuroscience, Univ. Tokushima & 2Toa Medicine Co., Ltd.)


9:26 A2-34

Inhibition of cytomegalocvirus replication by KANPO (Japanese herbal medicine)

○T. Murayama1, N. Yamaguchi2, S. Shimizu2, Y. Eizuru1

(1Cneter Chron. Viral Dis., Fac. Med. Kagoshima Univ., 2Dept. Serology Kanazawa Med. Univ.)


9:39 A2-35

Effect of functional nucleic acid on animal model of herpes infection

○Yoko Shoji, Hideki Nakashima

(Department of Microbiology, St. Marianna University School of Medicine)


9:52 A2-36

Differential mutation patterns in the thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 clones passaged in the presence of acyclovir or penciclovir

○Tatsuo Suzutani1, Ken Ishioka1, Erik De Clercq3, Kei Ishibashi1, Hisatoshi Kaneko1, Shuuichi Mori1, Masayuki Saijo2

(1Dept of Microbiology, Fukushima Med. University, 2Dept. of Special Pathogen Lab., Nat. Inst. of Infect. Dis., 3Rega Inst. for Med. Res.)


10:0510:20 Break

2nd Symposium of High Technology Research Center

(Chiba Institute of Technology)

Program
January 28 (Tue), 2003
10:20; Welcome (H.Uno, President of Chiba Institute of

Technology)
Chair: H. Shiota

10:20; PL-1:H. J. Field: Chemotherapy of Herpes Simplex Virus:

Past, Present, and Future Prospects

(Centre for Veterinary Science, Cambridge University, UK)


Chairs: N. Yamamoto, C.A. Stoddart

10:55; PL-2:N. Yamamoto: Human Retrovirus Studies in SCID Mice

(Department of Microbiology and Molecular Virology, Tokyo

Medical and Dental University, Japan)
11:30; PL-3:T. Nakayama: Th1/Th2cell differentiation and NKT cell

immune system.

(Department of Medical Immunology, Graduate School of

Medicine, Chiba University, Japan)

12:05~13:15 Lunch


13:15 HCV-an overview

K. Shimotohno
Chairs: K.Shimotohno, R. Bartenschlager

13:35; PL-4: K. Shimotohno: The roles of HCV proteins on cell

proliferation

(Institute for Virus Research, Kyoto University, Japan)


14:10; PL-P5: R. Bartenschlager: The hepatitis C virus replicon

system: a powerful tool for basic research and drug

discovery

(Department for Molecular Virology, University of

Heidelberg, Germany)

14:45; PL-6:M. Kohara: Reverse genetic approach to hepatitis C virus

infection and replication

(Department of Microbiology and Cell Biology, Tokyo

Metropolitan Institute of Medical Japan)

15:20~15:45 Break

Chairs: N. M. Kneteman, Y. Matsuura

15:45; PL-7:Y. Matsuura: Infection mechanisms of hepatitis C virus

(Research Center for Emerging Infectious Diseases

Research Institute for Microbial Diseases, Osaka

University, Japan)


16:20; PL-8: N. M. Kneteman: A Mouse Model of Hepatitis C Virus

Infection

(University of Alberta, Edmonton and Canadian Blood

Services, Canada)
16:55; PL-9: N. Kato: Anti hepatitis C virus activity of lactoferrin:

molecular mechanisms and clinical application.

(Department of Molecular Biology, Okayama University

Graduate School of Medicine and Dentistry, Japan)



Reception

Ginza Aster (Chinese Restaurant, Sunpedec 11F) 18:00~

January 29 (Wen), 2003
9:00

HIV-an overview

H. Mitsuya

(Kumamoto University School of Medicine, Japan)



Chairs: H. Mitsuya, F. Wong-Staal

9:35; PL-10:F. Wong-Staal1,2 :Identification of cellular factors for

HIV and HCV replication using inverse genomics.

(1Immusol Inc., San Diego CA;2Univ. Calif, San Diego,

CA, USA)
10:10; PL-11:C.A. Stoddart: IFN-alpha-mediated induction of CCR5

leads to expanded HIV-1 tropism in vivo

(Gladstone Institute of Virology and Immunology,

University of California at San Francisco, USA)

10:45~11:10 Beark

Chairs: E. De Clercq, M. Baba
11:10; PL-12:E. De Clercq: Antiviral potential of acyclic nucleoside

phosphoante analogues (Cidofovir, Adefovir, Tenofovir)

(Rega Institute for Medical Research, Katholieke

Universiteit Leuven, Belgium)

11:45; PL-13:D. R. Kuritzkes: Antiretroviral agents for the treatment

of HIV-1 infection

(Brigham & Women’s Hospital and Harvard Medical School

Boston, USA)
12:20; PL-14:M. Baba: HIV-1 gene expression and transcription: Is it

a possible target indeed for antiretroviral chemotherapy?

(Division of Human Retroviruses, Center for Chronic Viral



Diseases, Faculty of Medicine, Kagoshima University, Japan)

12:55 Closing remarks

Share with your friends:


The database is protected by copyright ©dentisty.org 2019
send message

    Main page